Standard BioTools (Standard BioTools) Interest Expense : $-4.6 Mil (TTM As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Standard BioTools Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Standard BioTools's interest expense for the three months ended in Dec. 2023 was $ -1.1 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-4.6 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Standard BioTools's Operating Income for the three months ended in Dec. 2023 was $ -14.9 Mil. Standard BioTools's Interest Expense for the three months ended in Dec. 2023 was $ -1.1 Mil. Standard BioTools did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Standard BioTools Interest Expense Historical Data

The historical data trend for Standard BioTools's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Standard BioTools Interest Expense Chart

Standard BioTools Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-4.28

-3.57

-3.82

-4.33

-4.57

Standard BioTools Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-1.19	-1.12	-1.13	-1.22	-1.10

Standard BioTools Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.6 Mil.

Standard BioTools (NAS:LAB) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Standard BioTools's Interest Expense for the three months ended in Dec. 2023 was $-1.1 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-14.9 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $34.4 Mil.

Standard BioTools's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Standard BioTools did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Standard BioTools (Standard BioTools) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Standard BioTools Inc (NAS:LAB) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

FLB:Germany FLB:Germany

Address

2 Tower Place, Suite 2000, South San Francisco, CA, USA, 94080

Website

https://www.standardbio.com

Standard BioTools Inc manufactures life science tools focused on the analysis of single cells and industrial applications of genomics. The company's segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.

Executives

Martin D Madaus	director	290 CONCORD ROAD, BILLERICA MA 01821
Jeffrey G. Black	officer: SVP & Chief Financial Officer	4955 DIRECTORS PLACE, SAN DIEGO CA 92121
Eli Casdin	director, 10 percent owner	1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Casdin Partners Master Fund, L.p.	director, 10 percent owner	WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Casdin Partners Fo1-msv, Lp	director	C/O CASDIN PARTNERS GP, LLC, 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Casdin Private Growth Equity Fund Ii Gp, Llc	director	1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Casdin Partners Gp, Llc	director, 10 percent owner	1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Casdin Capital, Llc	director, 10 percent owner	1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Casdin Private Growth Equity Fund Ii, L.p.	director	1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Fenel M Eloi	director	C/O INTERLEUKIN GENETICS INC, 135 BEAVER STREET, WALTHAM MA 02452
Caligan Partners Lp	10 percent owner	515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022
Frank Witney	director	940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Jeremy Steven Davis	officer: SVP Chief Commercial Officer	C/O FLUIDIGM CORPORATION, 2 TOWER PLACE, SUITE 2000, SOUTH SAN FRANCISCO CA 94080
Hanjoon Alex Kim	officer: Chief Operating Officer	C/O FLUIDIGM CORPORATION, 2 TOWER PLACE, SUITE 2000, SOUTH SAN FRANCISCO CA 94080
Michael Egholm	director, officer: President & CEO	1 FRANKLIN STREET, UNIT 3104, BOSTON MA 02110